Catégorie dans Recherche

Le chemin de la réussite doit se vivre au quotidien pas à pas : P A P :

▪ P pour passion

▪ A pour ambition

▪ P pour persévérance

Merci au REPAF ( Le Réseau des entrepreneurs et professionnels africains) pour m’avoir decerné ce 4 mai 2019 le prix du professionnel de l’année.

In adult patients with recurrent  Clostridium difficile infection, Fecal microbiota transplantation (FMT) performed better than Vancomycin alone or Fidaxomicin alone.

in this  open-labeled randomized trial published in the journal Gastroenterology, Hvas et al randomized 64 adults in one of the following three groups:

1- FMT by colonoscopy or nasojejunal tube, after 4–10 days of vancomycin (125 mg 4 times daily),

2- Fidaxomicin 200 mg twice daily  for 10 days

3- Vancomycin 125 mg 4 times daily for 10 days.

The primary outcome was combined clinical resolution and a negative result from a polymerase chain reaction test for Clostridium difficile toxin 8 weeks after the treatment.

The primary outcome was met in 71% of  FMT group,  33% in the Vancomycin group and  19% in Fidaxomicin group.

 

The future is bright for fecal transplantation in Clostridium difficile infection

 

Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection

Christian Lodberg Hvas,1 Simon Mark Dahl Jørgensen,1 Søren Peter Jørgensen,1 Merete Storgaard,2 Lars Lemming,3 Mette Mejlby Hansen,1 Christian Erikstrup,4 and Jens Frederik Dahlerup1

1 Department of Hepatology and Gastroenterology, Aarhus University Hospital, Aarhus, Denmark; 2 Department of Infectious Diseases, Aarhus University Hospital, Aarhus, Denmark; 3 Department of Clinical Microbiology, Aarhus University Hospital, Aarhus, Denmark; and 4 Department of Clinical Immunology, Aarhus University Hospital, Aarhus, Denmark

DOI: https://doi.org/10.1053/j.gastro.2018.12.019

A SYSTEMATIC REVIEW OF DISEASE-SPECIFIC QUALITY OF LIFE QUESTIONNAIRES IN CHILDREN AND ADULTS WITH CELIAC DISEASE.

Pegah Amir Yazdani, Pouneh Amir Yazdani, Martha Dirks, Prévost Jantchou. 

ESPGHAN 2019

---

TISSUE-TRANSGLUTAMINASE ANTIBODY HIGHER THAN 10 TIMES THE NORMAL VALUE IS A RELIABLE PREDICTIVE TEST OF VILLOUS ATROPHY IN PATIENTS WITH SUSPICION OF CELIAC DISEASE

T. Nguyen, O.V. Portolese, N. Patey, D. Dal Soglio, L. Oligny, M. Dirks, P. Jantchou

ESPGHAN2019

---

Worldwide Survey Of Current Digestive Endoscopy Practice in Children

Prevost Jantchou, Kiana Tchan, Noemie Laverdure, Lara Hart, Jennifer Ao, Mallory Chavannes

ESPGHAN2019

Cette année le 50 congrès du Digestive Disease Week [DDW] se tiendra à San Diego, Californie.

Voici nos abstracts qui seront présentés.

---

1- THE FACTORS ASSOCIATED WITH THE LEVELS OF PHYSICAL ACTIVITY IN ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE

Xin Yu Yang, Si Yuan Geng, Caitlyn Kanters, Sabrina Madagh, Lina Belmesk, Fella Chennou, Prevost Jantchou

Presentation Number: Mo1771

PDF

 

---

2- MEASUREMENT OF STRESS AND ANXIETY AND THE ASSOCIATED FACTORS IN PEDIATRIC GASTROENTEROLOGY PATIENTS

Matthew Abdaem, Si Yuan Geng, Shiyin Lao, Prevost Jantchou.

Presentation Number: Tu1602

PDF

 

---

3- TRENDS IN TNF-ALPHA INHIBITOR UTILIZATION IN CHILDREN WITH IBD DURING THE LAST 10 YEARS: 2009-2018

R. Iratni, F. Karkri , C. Deslandres,  P. Jantchou

Presentation Number: Sa1759

PDF

 

Le saviez vous…

Le don d’organes au Québec en chiffres

Ou

Parents: Attention certains jouets peuvent être dangereux pour les enfants surtout les jeunes enfants.

Enfants: Si vous voulez manger du poisson demander plutôt à maman de vous en cuisiner. Les poissons en éponge ne sont pas très nourrissants.

Abstracts présentés au congrès CDDW 2019 à Banff, AB :

http://cddw.cag-acg.org/sites/cag-acg/en/cddw

TITLE: RELATION BETWEEN VITAMIN D STATUS AND IBD ­RELATED HOSPITALIZATION IN CHILDREN WITH INFLAMMATORY BOWEL DISEASE TREATED WITH IMMUNOSUPPRESSANT OR BIOLOGICAL AGENTS

AUTHORS (FIRST NAME, LAST NAME): Fella Chennou 2 , Juliette Beaulieu 2 , Loures Habouri 2 , Prévost Jantchou 1,2

INSTITUTIONS (ALL): 1. CHU Sainte­Justine, Department of Pediatrics, Unit of Gastroenterology, Montreal, QC, Canada. 2 Research center of CHU Sainte­Justine, Montreal, QC, Canada.

TISSUE-TRANSGLUTAMINASE ANTIBODY HIGHER THAN 10 TIMES THE NORMAL VALUE IS A RELIABLE PREDICTIVE TEST OF VILLOUS ATROPHY IN PATIENTS WITH SUSPICION OF CELIAC DISEASE

T. Nguyen 2 , O.V. Portolese 1 , N. Patey 4 , D. Dal Soglio 4 , L. Oligny 4 , M. Dirks 3 , P. Jantchou 1,3

1. Research Center of CHU Sainte-Justine, Montreal, QC, Canada; 2. University of Montreal, Montreal, QC, Canada; 3. Gastroenterology Unit, Pediatrics Department, CHU Sainte-Justine, Montreal, QC, Canada; 4. Pathology Department, CHU Sainte-Justine, Montreal, QC, Canada

TRENDS IN THE CLINICAL PRESENTATION OF CELIAC DISEASE AT DIAGNOSIS IN CHILDREN IN QUEBEC

O.V. Portolese 3 , T. Nguyen 3 , D. Dal Soglio 1 , N. Patey 1 , L. Oligny 1 , M. Dirks 2 , P. Jantchou 2,3

1. CHU Sainte-Justine, Department of Pathology, Montreal, QC, Canada; 2. CHU Sainte-Justine Department of Pediatrics, Unit of Gastroenterology, Montreal, QC, Canada; 3. Research center of CHU Sainte-Justine, Montreal, QC, Canada

IS IBD-CONTROL QUESTIONNAIRE A RELIABLE PATIENT REPORTED OUTCOME IN ADOLESCENTS WITH INFLAMMATORY BOWEL DISEASE?

L. Belmesk 1 , S. Madagh 1 , X. Yang 1 , F. Chennou 1 , C. Kanters 1 , S. Geng 1 , L. Habouri 1 , P. Jantchou 1,2

1. CHU Ste-Justine Research Center, Montreal, QC, Canada; 2. CHU Ste-Justine Department of Pediatrics Unit of Gastroenterology , Montreal, QC, Canada

TRENDS IN TNF-ALPHA INHIBITOR UTILIZATION IN CHILDREN WITH IBD DURING THE LAST 10 YEARS: 2009-2018

R. Iratni 1 , F. Karkri 1 , C. Deslandres 1,2 , P. Jantchou 1,2,3

1. University of Montreal, Montreal, QC, Canada; 2. CHU Sainte-Justine, Department of Pediatrics, Unit of Gastroenterology, Montreal, QC, Canada; 3. Research center of CHU Sainte-Justine

 

Objectifs

1. Définir les recommandations concernant les niveaux requis d’activité physique chez l’enfant.
2. Définir les effets de l’activité physique sur la santé intestinale et la modulation du microbiome intestinal. 
3. Déterminer l’impact de l’activité physique sur l’inflammation systémique et intestinale.